SWOG S1406: Vemurafenib in Combination With Irinotecan and Cetuximab in BRAF V600E Metastatic CRC

June 2-6, 2017; Chicago, Illinois
In this open-label phase II study, addition of vemurafenib associated with significantly improved PFS and clinical activity in BRAF V600E mCRC patients previously treated with systemic chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 245 KB
Released: June 12, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

From Clinical Care Options (CCO), download a PDF featuring expert discussion of biomarkers in gastrointestinal cancers

John L. Marshall, MD Released: August 18, 2021

On-demand video from Clinical Care Options (CCO) with expert perspectives on using biomarkers to inform treatments for GI cancers

David H. Ilson, MD, PhD John L. Marshall, MD Eric Van Cutsem, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 16, 2021 Expired: August 15, 2022

Expert video from Clinical Care Options (CCO) on using biomarkers to inform treatments for GI cancers

Allison M. Cushman-Vokoun, MD, PhD John L. Marshall, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) Released: August 10, 2021 Expired: August 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue